Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Last updated: 2026-02-23 11:44:48 ET
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
Many important U.S. trading partners are facing higher duties after President Trump, reacting to a Supreme Court setback, set the rate on a new set of...
U.S. Trade Representative Jamieson Greer said "stand by" the trade deal agreements it has signed with its partners despite the Supreme Court's tariff...
The battle over the tariffs began on day one of the president's second term when he signed an executive order that let him impose a wide range of tariffs on virtually every U.S. trading partner.
Major U.S. trading partners expect President Trump—aka “Tariff Man”—to stick with his favorite policy tool.
The Supreme Court’s decision to invalidate many of President Trump’s tariffs raised questions about what would become of agreements struck with ma...
Supreme Court rules President Donald Trump exceeded his authority under emergency law to impose tariffs on more than 90 U.S. trading partners. The pos...
Peak XV says most of its new capital will target India as the firm prioritizes AI, fintech and cross-border bets while navigating recent partner depar...
America still bought a lot more than it sold, despite Trump’s shifting tariff policies with trade partners.
America still bought a lot more than it sold, despite Trump’s shifting tariff policies with trade partners.